Manipulating IL‐2 levels in patients is a focus of immunotherapeutic approaches, ranging from inhibition of IL‐2 for immunosuppression to its application as a vaccine adjuvant in cancer therapies (Abbas 2020; Walser et al. 2018; Bendickova and Fric 2020). The gene discussed is IL2; the disease is cancer.